



**Contact:**

Douglas Doerfler  
Chief Executive Officer  
MaxCyte, Inc.  
(301) 944-1700

**For Immediate Release**

**MaxCyte to Be Featured at the MAVA BioConnection 2005 Conference**

**Gaithersburg, MD, May 24, 2005** – MaxCyte, Inc., a clinical stage therapeutic company and pioneer in clinical scale, non-viral cell loading systems, announced today that Douglas A. Doerfler, President and CEO, will be presenting at the MAVA BioConnection 2005 Conference in Baltimore, Maryland, Baltimore Marriott Waterfront Hotel, Harborside Ballroom, on Tuesday, May 31, 2005, at 3:00PM EST.

Mr. Doerfler will provide a brief corporate overview and discuss the company's preclinical and clinical product candidates, partnering activities, and enabling technology for therapeutic development and biotherapeutic manufacturing.

"The investors who come to BioConnection 2005 will see some of the most fundable life sciences companies in the market today," said James Barrett, Co-Chair of BioConnection 2005 and General Partner of New Enterprise Associates. "These presenting companies demonstrate the continued strength and high quality of the entrepreneurs who are selected to participate in one of the venture industry's premier venture fairs."

Produced by the Mid-Atlantic Venture Association (MAVA), BioConnection 2005 is the premier venture event showcasing the region's most fundable healthcare companies. Founded in 1986, MAVA represents the collective interests of venture capitalists investing in the mid-Atlantic. Membership includes more than 500 venture capital professionals representing 125 firms collectively with more than \$10 Billion in capital under management. Numerous investors participate in MAVA's Life Sciences Investor Roundtable, a group of private equity and venture investors focused on biotech and life sciences investing. Through programming and networking, MAVA facilitates access to deal flow, institutional capital, and resources to support fund operations. In addition, more than 250 key professional service providers from the legal, financial, executive search and consulting fields are also MAVA members. For more information, please visit [www.mava.org](http://www.mava.org)

**About MaxCyte**

MaxCyte is a clinical stage therapeutics company developing both company sponsored and partnered therapeutics. The company's mission is to use its proprietary cell-loading technology to advance its therapeutic programs and enable developers of ex vivo cell therapies and manufacturers of biopharmaceutical products and therapies. MaxCyte's patented technology accelerates development timelines and reduces risk in bringing cell and gene therapies from bench to a clinical reality. MaxCyte's proprietary cell loading technology is closed and scalable, highly efficient, reproducible and reduces regulatory risk in *ex vivo* cell loading. MaxCyte's pipeline includes one